Recurrent subarachnoid hemorrhage (SAH) and acute renal artery thrombosis associated with treatment with 6-aminoacetic acid (GAA)

Abstract

EACA is an antifibrinolytic agent used to prevent rebleeding in SAH patients. Although EACA effectively reduces the occurrence of rebleeding, there have been reports of thrombotic complications, including worsening of symptoms and intracranial vascular thrombosis in patients with SAH, and small artery thrombosis in patients with fibrinolysis (fibrinolytic) syndrome. —The formation of fibrin thrombi or other thromboembolic phenomena in capillaries, but intravascular fibrin thrombi are common in fibrinolytic diseases, so the use of EACA should not be used alone as a cause of disseminated intravascular coagulation (DIC) or other consumption coagulopathies